InvestorsHub Logo
Followers 16
Posts 1062
Boards Moderated 0
Alias Born 09/01/2019

Re: smoki post# 14832

Monday, 07/19/2021 5:05:40 PM

Monday, July 19, 2021 5:05:40 PM

Post# of 16698
AGN had good Il-6 and low O-2 significant data. BS or is that real?
The decision to not go forward with Phase 3 because of costs and a waning COVID pandemic seems almost logical but to say data was not strong and just DROP Ifenprodil until after IPF/CC data???

Another stock is running well on weaker data for IL1 and IL-6, but they followed patients to 60 days to get something to present. (Mostly fluff, IMO) 195 patients and AGN treated 165.
Yep. screwed us hard with no Real explanation - no comment on what went right - no direction - and putting a snuffer on Ifenprodil by saying weak data??? WTF???

I have avoided bashing, butt, WTF? Inept? Stupid?...GLTA...

https://www.globenewswire.com/en/news-release/2021/05/12/2228023/0/en/Algernon-Pharmaceuticals-Announces-Ifenprodil-Reduced-Interleukin-6-in-Phase-2b-3-COVID-Study.html

https://www.globenewswire.com/en/news-release/2021/03/31/2202350/0/en/Algernon-Pharmaceuticals-Announces-Topline-Data-From-its-Phase-2b-3-COVID-19-Trial-of-Ifenprodil.html